These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2833086)

  • 21. Current status of canine urolithiasis.
    Finco DR
    J Am Vet Med Assoc; 1971 Feb; 158(3):327-35. PubMed ID: 4925719
    [No Abstract]   [Full Text] [Related]  

  • 22. [Conservative treatment of urolithiasis in children].
    Gadomska-Prokop K; Konopielko Z
    Pol Merkur Lekarski; 2000 Apr; 8(46):190-3. PubMed ID: 10897607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.
    Pak CY; Sakhaee K; Fuller CJ
    Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stone forming risk of calcium citrate supplementation in healthy postmenopausal women.
    Sakhaee K; Poindexter JR; Griffith CS; Pak CY
    J Urol; 2004 Sep; 172(3):958-61. PubMed ID: 15311008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Drug therapy of uric acid calculi--litholysis].
    Christoffersen JC
    Ugeskr Laeger; 1979 Feb; 141(9):563-7. PubMed ID: 34252
    [No Abstract]   [Full Text] [Related]  

  • 26. [Evaluation of treatment of uric acid urolithiasis and prevention of stone formation in children].
    Gadomska-Prokop K; Ryczkowska B; Tysarowska A
    Pediatr Pol; 1996 Aug; 71(8):685-7. PubMed ID: 8927472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dissolution of uric acid calculi with systemic alkalization.
    Kursh ED; Resnick MI
    J Urol; 1984 Aug; 132(2):286-7. PubMed ID: 6330382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of thiazide-induced hypokalemia without magnesium depletion by potassium-magnesium-citrate.
    Odvina CV; Mason RP; Pak CY
    Am J Ther; 2006; 13(2):101-8. PubMed ID: 16645424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Adverse effects of drug metaphylaxis of urolithiasis].
    Tuíková J; Kocvara R
    Cas Lek Cesk; 1989 Mar; 128(10):299-302. PubMed ID: 2720729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of diuretic therapy on spontaneous expulsion of urinary calculi, urinary pH, and crystalluria in lithiasic patients].
    Kaid-Omar Z; Belouatek A; Driouch A; Taleb-Bendiab H; Lacour B; Addou A; Daudon M
    Prog Urol; 2001 Jun; 11(3):450-7. PubMed ID: 11512457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologic treatment of uric acid calculi.
    Preminger GM
    Urol Clin North Am; 1987 May; 14(2):335-8. PubMed ID: 3576854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dissolution of obstructive uric acid calculi by percutaneous nephrostomy and in situ alkalinization].
    Maillet PJ; Fournet D; Pelle-Francoz D; Laville M; Pinet A
    J Radiol; 1986 Apr; 67(4):327-33. PubMed ID: 3020241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Dissolution of uric acid calculi].
    Cai SL; Yang SS; Wei KX
    Zhonghua Wai Ke Za Zhi; 1985 Sep; 23(9):562-4, 574-5. PubMed ID: 3004844
    [No Abstract]   [Full Text] [Related]  

  • 34. [The most important factor for active urinary stone formation in patients with urolithiasis].
    Simić-Ogrizović S; Dopsaj V; Jovicić S; Milenković D; Jovanović D; Nesić V
    Med Pregl; 2007; 60 Suppl 2():117-20. PubMed ID: 18928175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Metabolic factors associated with urolithiasis. Part II (author's transl)].
    Kuska J
    Przegl Lek; 1974; 31(12):982-6. PubMed ID: 4614334
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical outcome of percutaneous nephrolithotripsy and recurrence of stones].
    Nakajima H; Tanda H; Kato S; Ohnishi S; Ujiie T; Nanbu A; Ando T
    Hinyokika Kiyo; 1997 Aug; 43(8):549-53. PubMed ID: 9310776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dissolution of uric acid calculi with intravenous 1/6 molar lactate.
    Nieh PT; Wurzel RS
    Urology; 1985 Aug; 26(2):129-34. PubMed ID: 4024402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Adjustment of urine PH as effective tool for successful metaphylaxis of urinary stone disease. phytotherapy].
    Saenko VS; Lachinov EL; Zhantlisov DA; Gorbachev MI; Soltanov AA
    Urologiia; 2020 Jun; (3):104-110. PubMed ID: 32597596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medical therapy of stone disease: from prevention to promotion of passage options.
    Lipkin M; Shah O
    Curr Urol Rep; 2009 Jan; 10(1):29-34. PubMed ID: 19116093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational prevention of calcium urolithiasis.
    Butz M
    Urol Int; 1986; 41(5):387-92. PubMed ID: 3544440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.